Genentech Reports Positive Phase II Results for Petrelintide
SOUTH SAN FRANCISCO, California – March 6, 2026 Genentech announced positive topline results from the Phase II ZUPREME-1 clinical...
Genentech
Advertisement
FDA Approves Genentech’s Gazyva® for Lupus Nephritis, Marking Breakthrough in Autoimmune Kidney Care
NEW YORK, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by...
FDA Approves Jazz Pharma’s Zepzelca + Tecentriq Combo for ES-SCLC
DUBLIN, Oct. 2, 2025 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration...
Advertisement
